^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CBL0137

    i
    Other names: CBLC-137, CBL0137, CBL 0137, CBL137 IV, CBL0137 IV, CBLC137, CBLC 137
    Associations

    News

    Trials
    Company:
    Children's Oncology Group, Incuron, Statera BioPharma
    Drug class:
    FACT inhibitor
    Associations

    News

    Trials
    4ms
    PEPN2111: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (clinicaltrials.gov)
    P1/2, N=63, Recruiting, Children's Oncology Group | N=95 --> 63
    Enrollment change
    |
    AFP (Alpha-fetoprotein)
    |
    CBL0137
    9ms
    Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Fox Chase Cancer Center | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Mar 2025 --> Mar 2026 | Suspended --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CBL0137
    almost2years
    Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma (clinicaltrials.gov)
    P1, N=12, Suspended, Fox Chase Cancer Center | Trial completion date: Sep 2024 --> Sep 2025 | Recruiting --> Suspended | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial suspension • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CBL0137
    over2years
    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (clinicaltrials.gov)
    P1/2, N=95, Recruiting, Children's Oncology Group | Active, not recruiting --> Recruiting | N=38 --> 95
    Enrollment open • Enrollment change
    |
    AFP (Alpha-fetoprotein)
    |
    CBL0137
    over2years
    Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma (clinicaltrials.gov)
    P1, N=12, Recruiting, Fox Chase Cancer Center | Trial primary completion date: Nov 2024 --> Mar 2024
    Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CBL0137
    over3years
    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (clinicaltrials.gov)
    P1/2, N=38, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AFP (Alpha-fetoprotein)
    |
    CBL0137
    almost4years
    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (clinicaltrials.gov)
    P1/2, N=38, Recruiting, Children's Oncology Group | Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2026 --> Dec 2026
    Enrollment open • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    CBL0137
    almost4years
    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (clinicaltrials.gov)
    P1/2, N=38, Not yet recruiting, Children's Oncology Group | Trial primary completion date: Dec 2026 --> Feb 2026
    Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    |
    CBL0137
    4years
    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (clinicaltrials.gov)
    P1/2, N=38, Not yet recruiting, Children's Oncology Group | Initiation date: Sep 2021 --> Dec 2021
    Clinical • Trial initiation date
    |
    AFP (Alpha-fetoprotein)
    |
    CBL0137
    over4years
    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (clinicaltrials.gov)
    P1/2, N=4, Not yet recruiting, Children's Oncology Group
    Clinical • New P1/2 trial
    |
    AFP (Alpha-fetoprotein)
    |
    CBL0137
    5years
    CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer. (PubMed, Br J Cancer)
    Therefore, we investigated the potential effect of combining Rova-T and CBL in SCLC to eradicate TICs more effectively. Our preclinical studies report a novel and highly translatable therapeutic strategy of dual targeting TICs using Rova-T in combination with CBL to potentially increase survival of SCLC patients.
    Clinical • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3) • CBL (Cbl proto-oncogene)
    |
    Rova-T (rovalpituzumab tesirine) • CBL0137
    over5years
    CBL0137 administration suppresses human hepatocellular carcinoma cells proliferation and induces apoptosis associated with multiple cell death related proteins. (PubMed, Neoplasma)
    Moreover, HE staining and IHC staining for Ki-67 indicated that CBL0137 treatment could obviously induce cell apoptosis and suppress cell proliferation. CBL0137 treatment could effectively inhibit HCC cell proliferation and induce cell apoptosis associated with multiple factors expression.
    Journal • PARP Biomarker
    |
    TP53 (Tumor protein P53) • CBL (Cbl proto-oncogene) • NFKB1 (Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1) • CASP3 (Caspase 3) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • CASP7 (Caspase 7)
    |
    TP53 expression • BAX expression
    |
    CBL0137